Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema

Int Arch Allergy Immunol. 2016;170(2):101-7. doi: 10.1159/000447695. Epub 2016 Jul 28.

Abstract

Objective: To evaluate whether activated partial thromboplastin time (APTT) could be used in the laboratory diagnosis of hereditary or acquired angioedema (HAE or AAE) with and without C1 inhibitor (C1-INH) deficiency.

Methods: In a prospective investigation, APTT and other coagulation parameters were determined in 149 adult patients with various types of angioedema and in 26 healthy participants (HP).

Results: Mean APTT was significantly shortened in HAE-C1-INH type I (p < 0.0001) and type II (p = 0.0017) and in AAE-C1-INH (p < 0.0001) compared to the HP. APTT was shortened under the reference range (26-36 s) in 33/45 (73.3%) patients with HAE-C1-INH, 10/15 (66.7%) patients with AAE-C1-INH, 4/27 (14.8%) patients with HAE with normal C1-INH, 1/32 (3.1%) patients with histaminergic angioedema, 4/30 (13.3%) patients with nonhistaminergic angioedema and in 2/26 (7.7%) HP. Thus, a shortened APTT was obtained in 8-9 times more patients with angioedema due to C1-INH deficiency when compared to patients with various forms of angioedema with normal C1-INH and also to HP.

Conclusions: A shortened APTT may help to diagnose HAE-C1-INH and AAE-C1-INH when determination of C1-INH is not yet available.

MeSH terms

  • Angioedema / blood*
  • Angioedema / diagnosis*
  • Angioedemas, Hereditary / blood*
  • Angioedemas, Hereditary / diagnosis*
  • Biomarkers
  • Blood Coagulation
  • Blood Coagulation Tests
  • Complement C1 Inhibitor Protein
  • Complement C4
  • Diagnosis, Differential
  • Humans
  • Partial Thromboplastin Time*
  • Predictive Value of Tests
  • Prospective Studies

Substances

  • Biomarkers
  • Complement C1 Inhibitor Protein
  • Complement C4

Supplementary concepts

  • Acquired angioedema